51
|
Bae HC, Jeong SH, Kim JH, Lee H, Ryu WI, Kim MG, Son ED, Lee TR, Son SW. RIP4 upregulates CCL20 expression through STAT3 signalling in cultured keratinocytes. Exp Dermatol 2018; 27:1126-1133. [DOI: 10.1111/exd.13750] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2017] [Revised: 05/30/2018] [Accepted: 06/15/2018] [Indexed: 12/22/2022]
Affiliation(s)
- Hyun Cheol Bae
- Department of Dermatology; College of Medicine; Korea University; Seoul Korea
- Department of Biomedical Sciences; College of Medicine; Korea University; Seoul Korea
- Department of Orthopedic Surgery; Seoul National University Hospital; Seoul Korea
| | - Sang Hoon Jeong
- Department of Dermatology; College of Medicine; Korea University; Seoul Korea
- Department of Biomedical Sciences; College of Medicine; Korea University; Seoul Korea
| | - Jin Hee Kim
- Department of Dermatology; College of Medicine; Korea University; Seoul Korea
- Department of Biomedical Sciences; College of Medicine; Korea University; Seoul Korea
| | - Hana Lee
- Department of Dermatology; College of Medicine; Korea University; Seoul Korea
- Department of Biomedical Sciences; College of Medicine; Korea University; Seoul Korea
| | - Woo-In Ryu
- Department of Dermatology; College of Medicine; Korea University; Seoul Korea
- Department of Biomedical Sciences; College of Medicine; Korea University; Seoul Korea
| | - Min-Gyu Kim
- Department of Dermatology; College of Medicine; Korea University; Seoul Korea
- Department of Biomedical Sciences; College of Medicine; Korea University; Seoul Korea
| | - Eui Dong Son
- AmorePacific Corp/R&D Center; Yongin-si Gyeonggi-do Korea
| | - Tae Ryong Lee
- AmorePacific Corp/R&D Center; Yongin-si Gyeonggi-do Korea
| | - Sang Wook Son
- Department of Dermatology; College of Medicine; Korea University; Seoul Korea
- Department of Biomedical Sciences; College of Medicine; Korea University; Seoul Korea
| |
Collapse
|
52
|
Woods DM, Ramakrishnan R, Laino AS, Berglund A, Walton K, Betts BC, Weber JS. Decreased Suppression and Increased Phosphorylated STAT3 in Regulatory T Cells are Associated with Benefit from Adjuvant PD-1 Blockade in Resected Metastatic Melanoma. Clin Cancer Res 2018; 24:6236-6247. [PMID: 30131384 DOI: 10.1158/1078-0432.ccr-18-1100] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2018] [Revised: 07/10/2018] [Accepted: 08/16/2018] [Indexed: 12/12/2022]
Abstract
PURPOSE PD-1 blockade induces durable responses in patients with metastatic melanoma and prolongs relapse-free survival in patients with resected melanoma; however, current biomarkers do not consistently associate with patient responses. In this study, we investigated the impact of nivolumab therapy on peripheral blood regulatory T cells (Treg) and its relation to patient outcomes. EXPERIMENTAL DESIGN Peripheral blood Tregs and conventional CD4+ T cells from patients with resected high-risk melanoma treated with adjuvant nivolumab were assessed for gene expression changes by RNA-seq. Percentages of circulating Tregs and phosphorylated-STAT3 (pSTAT3) expression levels were assessed by flow cytometry and validated in an independent cohort of active disease patients. Suppressive function of Tregs was assessed in allogeneic mixed lymphocyte reactions. RESULTS Tregs from non-relapse patients had increased expression of proliferation associated genes. An increase in the proportion of circulating Tregs and pSTAT3 expression and a reduction in Treg-suppressive capacity were observed in non-relapsing, but not relapsing patient samples 13 weeks after starting treatment. In vitro blockade of PD-1 increased Treg percentages and pSTAT3 expression, and reduced Treg-suppressive function. PD-1 blockade also led to IL10 production by T cells, resulting in higher Treg proliferation. The addition of a STAT3 inhibitor ameliorated the increase in Tregs, enhanced suppressive function, and decreased T-cell IL10 production in vitro. CONCLUSIONS These results demonstrate that induction of pSTAT3, reduced suppressive function, and a paradoxical increase in Treg proliferation are novel correlates of patient benefit from PD-1 blockade.
Collapse
Affiliation(s)
- David M Woods
- New York University Langone Medical Center, New York, New York.
| | | | | | - Anders Berglund
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
| | - Kelly Walton
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
| | - Brian C Betts
- H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida
| | - Jeffrey S Weber
- New York University Langone Medical Center, New York, New York
| |
Collapse
|
53
|
Stockenhuber K, Hegazy AN, West NR, Ilott NE, Stockenhuber A, Bullers SJ, Thornton EE, Arnold IC, Tucci A, Waldmann H, Ogg GS, Powrie F. Foxp3 + T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8 + T cell response. J Exp Med 2018; 215:1987-1998. [PMID: 29980582 PMCID: PMC6080913 DOI: 10.1084/jem.20172094] [Citation(s) in RCA: 32] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 03/29/2018] [Accepted: 06/11/2018] [Indexed: 12/15/2022] Open
Abstract
Psoriasis is a complex inflammatory skin disease affecting ∼3% of the population worldwide. Although type I interferons (IFN-I) are thought to be involved in its pathogenesis, the details of this relationship remain elusive. Here we show that in a murine model of imiquimod-driven psoriatic skin inflammation, Foxp3+ regulatory T cells (T reg cells) control inflammation severity by restraining IFN-I. Depletion of T reg cells induces IFN-I and IFN-stimulated gene expression, and leads to accumulation of CD8+ T cells in lesional skin. Mononuclear phagocytes (MNPs) were the source of IFN-I, and their depletion reversed the effect of T reg cell depletion. Blockade of IFN-I signaling abolished CD8+ T cell infiltration and excess inflammation in the skin of T reg cell-depleted mice. Depletion of CD8+ T cells attenuated pathology, confirming their role as critical effector cells downstream of IFN-I. Our results describe an unexpected role for T reg cells in restraint of an MNP-IFN-I-driven CD8+ T cell response during psoriasiform skin inflammation. These findings highlight a pathway with potential relevance for the treatment of early-stage disease.
Collapse
Affiliation(s)
- Krista Stockenhuber
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
- Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
- MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Ahmed N Hegazy
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
- Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - Nathaniel R West
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
- Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - Nicholas E Ilott
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
| | - Alexander Stockenhuber
- Wellcome Trust Centre for Human Genetics, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Samuel J Bullers
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
| | - Emily E Thornton
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
| | - Isabelle C Arnold
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
- Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| | - Andrea Tucci
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
| | - Herman Waldmann
- Sir William Dunn School of Pathology, University of Oxford, Oxford, UK
| | - Graham S Ogg
- MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
| | - Fiona Powrie
- Kennedy Institute of Rheumatology, University of Oxford, Oxford, UK
- Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK
| |
Collapse
|
54
|
Myles IA, Anderson ED, Earland NJ, Zarember KA, Sastalla I, Williams KW, Gough P, Moore IN, Ganesan S, Fowler CJ, Laurence A, Garofalo M, Kuhns DB, Kieh MD, Saleem A, Welch PA, Darnell DA, Gallin JI, Freeman AF, Holland SM, Datta SK. TNF overproduction impairs epithelial staphylococcal response in hyper IgE syndrome. J Clin Invest 2018; 128:3595-3604. [PMID: 30035749 PMCID: PMC6063472 DOI: 10.1172/jci121486] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2018] [Accepted: 06/06/2018] [Indexed: 12/13/2022] Open
Abstract
Autosomal dominant hyper IgE syndrome (AD-HIES), or Job's syndrome, is a primary immune deficiency caused by dominant-negative mutations in STAT3. Recurrent Staphylococcus aureus skin abscesses are a defining feature of this syndrome. A widely held hypothesis that defects in peripheral Th17 differentiation confer this susceptibility has never been directly evaluated. To assess the cutaneous immune response in AD-HIES, we induced suction blisters in healthy volunteers (HVs) and patients with AD-HIES and then challenged the wound with lethally irradiated bacteria. We show that cutaneous production of IL-17A and IL-17F was normal in patients with AD-HIES. Overproduction of TNF-α differentiated the responses in AD-HIES from HVs. This was associated with reduced IL-10 family signaling in blister-infiltrating cells and defective epithelial cell function. Mouse models of AD-HIES recapitulated these aberrant epithelial responses to S. aureus and involved defective epithelial-to-mesenchymal transition (EMT) rather than a failure of bacterial killing. Defective responses in mouse models of AD-HIES and primary keratinocyte cultures from patients with AD-HIES could be reversed by TNF-α blockade and by drugs with reported modulatory effects on EMT. Our results identify these as potential therapeutic approaches in patients with AD-HIES suffering S. aureus infections.
Collapse
Affiliation(s)
- Ian A. Myles
- Laboratory of Clinical Immunology and Microbiology, and
| | | | | | - Kol A. Zarember
- Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA
| | - Inka Sastalla
- Laboratory of Clinical Immunology and Microbiology, and
| | | | - Portia Gough
- Laboratory of Clinical Immunology and Microbiology, and
| | - Ian N. Moore
- Infectious Disease and Pathogenesis Section, Comparative Medicine Branch, NIAID, NIH, Rockville, Maryland, USA
| | - Sundar Ganesan
- Biological Imaging Section, Research Technology Branch, NIAID, NIH, Bethesda, Maryland, USA
| | | | - Arian Laurence
- Translational Gastroenterology Unit, John Radcliffe Hospital, Oxford University, Oxford, United Kingdom
| | - Mary Garofalo
- Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA
| | - Douglas B. Kuhns
- Applied Developmental Research Directorate, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA
| | - Mark D. Kieh
- Laboratory of Clinical Immunology and Microbiology, and
| | - Arhum Saleem
- Laboratory of Clinical Immunology and Microbiology, and
| | | | | | - John I. Gallin
- Laboratory of Host Defenses, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA
| | | | | | | |
Collapse
|
55
|
Ahn R, Yan D, Chang HW, Lee K, Bhattarai S, Huang ZM, Nakamura M, Singh R, Afifi L, Taravati K, Munoz-Sandoval P, Pauli M, Rosenblum MD, Liao W. RNA-seq and flow-cytometry of conventional, scalp, and palmoplantar psoriasis reveal shared and distinct molecular pathways. Sci Rep 2018; 8:11368. [PMID: 30054515 PMCID: PMC6063960 DOI: 10.1038/s41598-018-29472-w] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Accepted: 07/04/2018] [Indexed: 02/08/2023] Open
Abstract
It has long been recognized that anatomic location is an important feature for defining distinct subtypes of plaque psoriasis. However, little is known about the molecular differences between scalp, palmoplantar, and conventional plaque psoriasis. To investigate the molecular heterogeneity of these psoriasis subtypes, we performed RNA-seq and flow cytometry on skin samples from individuals with scalp, palmoplantar, and conventional plaque psoriasis, along with samples from healthy control patients. We performed differential expression analysis and network analysis using weighted gene coexpression network analysis (WGCNA). Our analysis revealed a core set of 763 differentially expressed genes common to all sub-types of psoriasis. In contrast, we identified 605, 632, and 262 genes uniquely differentially expressed in conventional, scalp, and palmoplantar psoriasis, respectively. WGCNA and pathway analysis revealed biological processes for the core genes as well as subtype-specific genes. Flow cytometry analysis revealed a shared increase in the percentage of CD4+ T regulatory cells in all psoriasis subtypes relative to controls, whereas distinct psoriasis subtypes displayed differences in IL-17A, IFN-gamma, and IL-22 production. This work reveals the molecular heterogeneity of plaque psoriasis and identifies subtype-specific signaling pathways that will aid in the development of therapy that is appropriate for each subtype of plaque psoriasis.
Collapse
Affiliation(s)
- Richard Ahn
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States.
| | - Di Yan
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
- School of Medicine, Case Western Reserve University, Cleveland, OH, United States
| | - Hsin-Wen Chang
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Kristina Lee
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Shrishti Bhattarai
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Zhi-Ming Huang
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Mio Nakamura
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Rasnik Singh
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Ladan Afifi
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Keyon Taravati
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Priscila Munoz-Sandoval
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Mariela Pauli
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Michael D Rosenblum
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| | - Wilson Liao
- Department of Dermatology, University of California, San Francisco, San Francisco, CA, United States
| |
Collapse
|
56
|
Aarebrot AK, Solberg SM, Davies R, Bader LI, Holmes TD, Gavasso S, Bryceson YT, Jonsson R, Sandvik LF, Appel S. Phosphorylation of intracellular signalling molecules in peripheral blood cells from patients with psoriasis on originator or biosimilar infliximab. Br J Dermatol 2018; 179:371-380. [PMID: 29274242 DOI: 10.1111/bjd.16269] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/18/2017] [Indexed: 12/11/2022]
Abstract
BACKGROUND Psoriasis vulgaris is a chronic, inflammatory skin disease characterized by a dysregulated immune response and it is associated with substantial systemic comorbidities. Biological drugs such as tumour necrosis factor (TNF)-α inhibitors can ameliorate the disease but are expensive. Biosimilar drugs have the same amino-acid sequence as the originator, but differences in manufacturing can affect biological activity, efficacy and tolerability. OBJECTIVES To explore potential differences in intracellular phosphorylation of signalling molecules in peripheral blood cells from patients with psoriasis treated with the TNF-α inhibitor infliximab compared with healthy controls, and to investigate if the phosphorylation pattern was influenced by switching from the originator infliximab to the biosimilar CT-P13. METHODS By flow cytometry, we measured phosphorylation of nuclear factor kappa B, extracellular signal-regulated kinase 1/2, p38 mitogen-activated protein kinase and signal transducer and activator of transcription 3, before and after TNF-α stimulation in monocytes and T, B, natural killer and CD3+ CD56+ cells from 25 patients with psoriasis treated with infliximab and 19 healthy controls. RESULTS At inclusion, phosphorylation levels of peripheral blood mononuclear cells (PBMCs) were increased in patients with psoriasis compared with healthy controls, even though clinical remission had already been achieved. Phosphorylation levels declined in patients on both originator infliximab and biosimilar during continued treatment. No significant differences were detected between the two medications after 12 months. CONCLUSIONS Patients with psoriasis on infliximab have higher activation levels of PBMCs than do healthy controls, possibly reflecting systemic inflammation. Switching from the originator infliximab to biosimilar CT-P13 did not affect phosphorylation levels or clinical parameters, suggesting that CT-P13 is a noninferior treatment alternative to the originator infliximab.
Collapse
Affiliation(s)
- A K Aarebrot
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - S M Solberg
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.,Department of Dermatology, Haukeland University Hospital, Bergen, Norway
| | - R Davies
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - L I Bader
- Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease (BEaBiRD), Department of Rheumatology, Haukeland University Hospital, Bergen, Norway.,Department of Clinical Science, University of Bergen, Bergen, Norway
| | - T D Holmes
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - S Gavasso
- Neuroimmunology Laboratory, Department of Neurology, Haukeland University Hospital, Bergen, Norway.,Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Y T Bryceson
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.,Centre for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
| | - R Jonsson
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway.,Bergen Group of Epidemiology and Biomarkers in Rheumatic Disease (BEaBiRD), Department of Rheumatology, Haukeland University Hospital, Bergen, Norway
| | - L F Sandvik
- Department of Dermatology, Haukeland University Hospital, Bergen, Norway.,Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - S Appel
- Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway
| |
Collapse
|
57
|
Owczarczyk-Saczonek A, Czerwińska J, Placek W. The role of regulatory T cells and anti-inflammatory cytokines in psoriasis. ACTA DERMATOVENEROLOGICA ALPINA PANNONICA ET ADRIATICA 2018. [DOI: 10.15570/actaapa.2018.4] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
58
|
Tang L, He S, Wang X, Liu H, Zhu Y, Feng B, Su Z, Zhu W, Liu B, Xu F, Li C, Zhao J, Zheng X, Lu C, Zheng G. Cryptotanshinonereduces psoriatic epidermal hyperplasia via inhibiting the activation of STAT3. Exp Dermatol 2018; 27:268-275. [PMID: 29427477 DOI: 10.1111/exd.13511] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/19/2018] [Indexed: 12/11/2022]
Affiliation(s)
- Lipeng Tang
- Department of Pharmacology of Traditional Chinese Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
- The Postdoctoral Research Station; Guangzhou University of Chinese Medicine; Guangzhou, Guangdong China
| | - Songmin He
- Department of Pharmacology of Traditional Chinese Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Xieqi Wang
- The Second Clinical Medical College; Guangzhou University of Chinese Medicine; Guangzhou China
| | - Hongying Liu
- Department of Pathology; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Ying Zhu
- Department of Pharmacology of Traditional Chinese Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Bing Feng
- Department of Pharmacology of Traditional Chinese Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Zuqing Su
- Department of Pharmacology of Traditional Chinese Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Wei Zhu
- Traditional Chinese Medicine Material Basic Research Team; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Bo Liu
- Department of Chemical Research and Structural Optimization based on Chinese Material Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Fangfang Xu
- Department of Chemical Research and Structural Optimization based on Chinese Material Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Chutian Li
- Department of Pathology; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Jie Zhao
- Department of Pathology; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Xirun Zheng
- Department of Pathology; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Chuanjian Lu
- Department of Dermatology; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| | - Guangjuan Zheng
- Department of Pharmacology of Traditional Chinese Medicine; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
- Department of Pathology; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine; Guangzhou China
| |
Collapse
|
59
|
Umar M, Sastry KS, Al Ali F, Al-Khulaifi M, Wang E, Chouchane AI. Vitamin D and the Pathophysiology of Inflammatory Skin Diseases. Skin Pharmacol Physiol 2018; 31:74-86. [DOI: 10.1159/000485132] [Citation(s) in RCA: 77] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2017] [Accepted: 11/07/2017] [Indexed: 12/13/2022]
|
60
|
Calautti E, Avalle L, Poli V. Psoriasis: A STAT3-Centric View. Int J Mol Sci 2018; 19:ijms19010171. [PMID: 29316631 PMCID: PMC5796120 DOI: 10.3390/ijms19010171] [Citation(s) in RCA: 132] [Impact Index Per Article: 22.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Revised: 12/22/2017] [Accepted: 01/04/2018] [Indexed: 12/24/2022] Open
Abstract
Signal Transducer and Activator of Transcription (STAT)3 has recently emerged as a key player in the development and pathogenesis of psoriasis and psoriatic-like inflammatory conditions. Indeed, STAT3 hyperactivation has been reported in virtually every cell type involved in disease initiation and maintenance, and this factor mediates the signal of most cytokines that are involved in disease pathogenesis, including the central Interleukin (IL)-23/IL-17/IL-22 axis. Despite the recent availability of effective biological agents (monoclonal antibodies) against IL-17 and IL-23, which have radically changed the current standard of disease management, the possibility of targeting either STAT3 itself or, even better, the family of upstream activators Janus kinases (JAK1, 2, 3, and TYK2) offers additional therapeutic options. Due to the oral/topical administration modality of these small molecule drugs, their lower cost, and the reduced risk of eliciting adverse immune responses, these compounds are being actively scrutinized in clinical settings. Here, we summarize the main pathological features of psoriatic conditions that provide the rationale for targeting the JAK/STAT3 axis in disease treatment.
Collapse
Affiliation(s)
- Enzo Calautti
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
| | - Lidia Avalle
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
| | - Valeria Poli
- Department of Molecular Biotechnology and Health Sciences, University of Torino, 10126 Torino, Italy.
| |
Collapse
|
61
|
Abstract
INTRODUCTION The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis. Human IL-23 is primarily produced by antigen-presenting cells and induces and maintains differentiation of Th17 cells and Th22 cells, a primary cellular source of proinflammatory cytokines such as IL-17 and IL-22, which mediate the epidermal hyperplasia, keratinocyte immune activation and tissue inflammation inherent in psoriasis. Agents that target the p40 subunit common to both IL-12 and IL-23 have shown robust clinical activity, but selectivity for IL-23p19 could offer advantages in efficacy and safety with respect to anti-p40 blockade. Areas covered: Relevant references regarding the role of the IL-23/IL-17 pathway in the pathogenesis of psoriasis/psoriatic arthritis and clinical trials with IL-23p40 and IL-23p19 blocking agents were obtained through a literature search in MEDLINE/Pubmed for articles published until November 2016. Moreover, ongoing registered clinical trials (RCTs) of moderate-to-severe psoriasis and psoriatic arthritis were searched through clinicaltrials.gov website, and a manual search was made for pertinent communications at the 2016 American Academy of Dermatology and European Academy of Dermatology and Venereology meetings. Expert commentary: There are potential advantages in selective blockade of the IL23-specific p19 subunit with respect to distal blockade of IL-17A or its receptor. Acting upstream in the IL-23/IL-17 cytokine pathway is likely to reduce the expression of multiple pro-inflammatory cytokines acting on keratinocytes -including IL-17F, IL-21 and IL-22-, in addition to IL-17A. On the other hand, safety data thus far suggest that these drugs might be devoid of some adverse effects of IL-17A blockade that seem to be class related, such as mucocutaneous Candida infections or triggering or worsening of inflammatory bowel disease. Specific IL-23p19 blockade with high-affinity monoclonal antibodies seems to be able to induce long-term remissions of the activity in psoriasis and might eventually represent a paradigm change in the treatment of psoriasis. The results of phase III and comparative head-to-head trials with these agents are eagerly awaited.
Collapse
Affiliation(s)
- Lluís Puig
- a Department of Dermatology, Hospital de la Santa Creu i Sant Pau , Universitat Autònoma de Barcelona , Barcelona , Catalonia , Spain
| |
Collapse
|
62
|
Li X, Levine H. Bistability of the cytokine-immune cell network in a cancer microenvironment. CONVERGENT SCIENCE PHYSICAL ONCOLOGY 2017. [DOI: 10.1088/2057-1739/aa6c07] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
63
|
Abstract
Psoriasis is a complex chronic relapsing inflammatory disease. Although the exact mechanism remains unknown, it is commonly accepted that the development of psoriasis is a result of multi-system interactions among the epidermis, dermis, blood vessels, immune system, neuroendocrine system, metabolic system, and hematopoietic system. Many cell types have been confirmed to participate in the pathogenesis of psoriasis. Here, we review the stem cell abnormalities related to psoriasis that have been investigated recently.
Collapse
|
64
|
Pesenacker AM, Cook L, Levings MK. The role of FOXP3 in autoimmunity. Curr Opin Immunol 2016; 43:16-23. [PMID: 27544816 DOI: 10.1016/j.coi.2016.07.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2016] [Accepted: 07/24/2016] [Indexed: 12/11/2022]
Abstract
FOXP3 controls the development and function of T regulatory cells (Tregs). Autoimmunity is linked to changes in FOXP3 activity that can occur at multiple levels and lead to Treg dysfunction. For example, changes in IL-2 signaling, FOXP3 transcription and/or post-translational modifications can all contribute to loss of self-tolerance. As additional pathways of FOXP3 regulation are elucidated, new therapeutic approaches to increase Treg activity either by cell therapy or pharmacological intervention are being tested. Early success from pioneering studies of Treg-based therapy in transplantation has promoted the undertaking of similar studies in autoimmunity, with emerging evidence for the effectiveness of these approaches, particularly in the context of type 1 diabetes.
Collapse
Affiliation(s)
- Anne M Pesenacker
- Department of Surgery, University of British Columbia, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada
| | - Laura Cook
- Department of Surgery, University of British Columbia, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada
| | - Megan K Levings
- Department of Surgery, University of British Columbia, Canada; BC Children's Hospital Research Institute, Vancouver, BC, Canada.
| |
Collapse
|
65
|
Lochmatter C, Fischer R, Charles PD, Yu Z, Powrie F, Kessler BM. Integrative Phosphoproteomics Links IL-23R Signaling with Metabolic Adaptation in Lymphocytes. Sci Rep 2016; 6:24491. [PMID: 27080861 PMCID: PMC4832251 DOI: 10.1038/srep24491] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2015] [Accepted: 03/30/2016] [Indexed: 12/15/2022] Open
Abstract
Interleukin (IL)-23 mediated signal transduction represents a major molecular mechanism underlying the pathology of inflammatory bowel disease, Crohn's disease and ulcerative colitis. In addition, emerging evidence supports the role of IL-23-driven Th17 cells in inflammation. Components of the IL-23 signaling pathway, such as IL-23R, JAK2 and STAT3, have been characterized, but elements unique to this network as compared to other interleukins have not been readily explored. In this study, we have undertaken an integrative phosphoproteomics approach to better characterise downstream signaling events. To this end, we performed and compared phosphopeptide and phosphoprotein enrichment methodologies after activation of T lymphocytes by IL-23. We demonstrate the complementary nature of the two phosphoenrichment approaches by maximizing the capture of phosphorylation events. A total of 8202 unique phosphopeptides, and 4317 unique proteins were identified, amongst which STAT3, PKM2, CDK6 and LASP-1 showed induction of specific phosphorylation not readily observed after IL-2 stimulation. Interestingly, quantitative analysis revealed predominant phosphorylation of pre-existing STAT3 nuclear subsets in addition to translocation of phosphorylated STAT3 within 30 min after IL-23 stimulation. After IL-23R activation, a small subset of PKM2 also translocates to the nucleus and may contribute to STAT3 phosphorylation, suggesting multiple cellular responses including metabolic adaptation.
Collapse
Affiliation(s)
- Corinne Lochmatter
- Kennedy Institute, Nuffield Department of Orthopedics Research Medical Science, Roosevelt Drive, Oxford OX3 7LF, UK
- Ludwig Institute for Cancer Research Ltd, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, UK
| | - Roman Fischer
- Kennedy Institute, Nuffield Department of Orthopedics Research Medical Science, Roosevelt Drive, Oxford OX3 7LF, UK
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK
| | - Philip D. Charles
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK
| | - Zhanru Yu
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK
| | - Fiona Powrie
- Kennedy Institute, Nuffield Department of Orthopedics Research Medical Science, Roosevelt Drive, Oxford OX3 7LF, UK
| | - Benedikt M. Kessler
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford OX3 7FZ, UK
| |
Collapse
|